H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

Yi-Nong Chen; Ying-Lin Chen; Wan-Ming Chen; Mingchih Chen; Ben-Chang Shia; Jenq-Yuh Ko; Szu-Yuan Wu

doi:10.32604/or.2022.028449

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

Oncol Res. 2023 Mar 1;31(1):23-34. doi: 10.32604/or.2022.028449. eCollection 2023.

Authors

Yi-Nong Chen¹, Ying-Lin Chen¹, Wan-Ming Chen^{2

3}, Mingchih Chen^{2

3}, Ben-Chang Shia^{2

3}, Jenq-Yuh Ko^{1

4}, Szu-Yuan Wu^{2

3

5

6

7

8

9

10

11}

Affiliations

¹ Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
² Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan.
³ Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan.
⁴ Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan.
⁶ Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
⁷ Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
⁸ Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.
⁹ Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
¹⁰ Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
¹¹ Department of Management, College of Management, Fo Guang University, Yilan, Taiwan.

Abstract

This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384 patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users (adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of HNC in T2DM patients.

Keywords: H1-Antihistamine; Head and neck cancer; Incidence; Incidence rate; Type 2 diabetes.

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Head and Neck Neoplasms* / epidemiology
Histamine Antagonists
Humans

Substances

Histamine Antagonists